항바이러스제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 유형별, 약물 종류별, 유통 채널별, 용도별, 지역별, 경쟁별(2020-2030년)

The Global Anti-Viral Drugs Market, valued at USD 77.10 Billion in 2024, is projected to experience a CAGR of 3.89% to reach USD 96.94 Billion by 2030. Antiviral drugs are pharmaceutical agents developed to inhibit viral replication and proliferation within a host, thereby treating or preventing viral infections such as HIV, hepatitis, and influenza. The market's growth is primarily driven by the escalating global incidence of viral diseases, substantial investments in pharmaceutical research and development, and proactive public health campaigns for infection control.

Key Market Drivers

The increasing global prevalence of viral infections stands as a significant driver for the antiviral drugs market, creating an enduring demand for effective therapeutic solutions. The continuous emergence of new viral strains and the persistent burden of established pathogens pose substantial public health challenges, from seasonal outbreaks to widespread epidemics. For example, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS) in its 2023 Global AIDS Update, an estimated 1.3 million people worldwide became newly infected with HIV in 2022. This ongoing incidence necessitates the development of advanced antiviral treatments to manage and prevent disease progression, thereby directly influencing market demand for these crucial pharmaceutical products.

Key Market Challenges

The rapid evolution of viral resistance to existing therapeutic agents presents a significant obstacle to the sustained growth of the global anti-viral drugs market. As viruses mutate and develop resistance, the efficacy of current treatments diminishes, necessitating the continuous development of novel compounds. This ongoing requirement for new pharmaceutical agents directly impedes market expansion by escalating development costs and increasing regulatory complexities.

Key Market Trends

The growing adoption of AI-driven drug discovery for antivirals represents a significant shift in pharmaceutical research, aiming to accelerate the identification and development of novel compounds. This trend leverages advanced computational techniques to analyze vast biological datasets, predict molecular properties, and optimize drug designs, thereby streamlining the notoriously lengthy and expensive drug development process. According to a survey from cloud vendor Rackspace Technology and Dell/VMware conducted in October 2023, 67% of pharmaceutical companies planned to increase their IT investments, including AI, over the subsequent 12 months, highlighting this strategic pivot.

Key Market Players

• F. Hoffmann-La Roche Ltd
• GSK plc.
• AbbVie, Inc.
• Merck & Co., Inc.
• Johnson & Johnson Services, Inc.
• Bristol-Myers Squibb Company
• Aurobindo Pharma
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.

Report Scope:

In this report, the Global Anti-Viral Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anti-Viral Drugs Market, By Type:

• Branded
• Generics

Anti-Viral Drugs Market, By Drug Class:

• DNA Polymerase Inhibitors
• Reverse Transcriptase Inhibitors
• Protease Inhibitors
• Neuraminidase Inhibitors
• Others

Anti-Viral Drugs Market, By Application:

• HIV
• Hepatitis
• Herpes
• Influenza
• Others

Anti-Viral Drugs Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Anti-Viral Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Anti-Viral Drugs Market.

Available Customizations:

Global Anti-Viral Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anti-Viral Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Branded, Generics)
  • 5.2.2. By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Others)
  • 5.2.3. By Application (HIV, Hepatitis, Herpes, Influenza, Others)
  • 5.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Anti-Viral Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drug Class
  • 6.2.3. By Application
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Anti-Viral Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drug Class
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Anti-Viral Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drug Class
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Anti-Viral Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drug Class
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By Distribution Channel

7. Europe Anti-Viral Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Drug Class
  • 7.2.3. By Application
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Anti-Viral Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drug Class
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Anti-Viral Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drug Class
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Anti-Viral Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drug Class
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Anti-Viral Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Drug Class
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Anti-Viral Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Drug Class
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Anti-Viral Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Drug Class
  • 8.2.3. By Application
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Anti-Viral Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drug Class
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Anti-Viral Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drug Class
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Anti-Viral Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drug Class
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Anti-Viral Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Drug Class
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Anti-Viral Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Drug Class
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Anti-Viral Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug Class
  • 9.2.3. By Application
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Anti-Viral Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drug Class
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Anti-Viral Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug Class
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Anti-Viral Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drug Class
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By Distribution Channel

10. South America Anti-Viral Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Drug Class
  • 10.2.3. By Application
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Anti-Viral Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Drug Class
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Anti-Viral Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Drug Class
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Anti-Viral Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Drug Class
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Anti-Viral Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F. Hoffmann-La Roche Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. GSK plc.
• 15.3. AbbVie, Inc.
• 15.4. Merck & Co., Inc.
• 15.5. Johnson & Johnson Services, Inc.
• 15.6. Bristol-Myers Squibb Company
• 15.7. Aurobindo Pharma
• 15.8. Cipla Limited
• 15.9. Dr. Reddy's Laboratories Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer